Bipolar Disorder Market to Reach $15.5 billion by 2035s
Bipolar disorder market was valued at $9.7 billion in 2025 and is projected to reach $15.5 billion by 2035, growing at a CAGR of 4.8% from 2026 to 2035. The rising global burden of mental health disorders primarily drives growth. According to the World Health Organization (September 2025), more than 1 billion people worldwide are living with mental health conditions, highlighting a substantial unmet need for treatment and care. This burden includes bipolar disorder, which affects around 37 million people globally, significantly driving demand for effective therapies. The increasing prevalence is pushing healthcare systems to expand mental health services and treatment access. Additionally, improved diagnosis rates and growing awareness are enabling earlier intervention and long-term disease management. Expanding access to pharmacotherapy is further accelerating market growth.
Browse the full report description of “Bipolar Disorder Market Size, Share & Trends Analysis Report by Drug Class (Mood Stabilizers, Antipsychotics, Antidepressants, Combination Therapies), By Disorder Type (Bipolar I Disorder, Bipolar II Disorder, Cyclothymic Disorder), By Episode (Manic Episodes, Depressive Episodes, Mixed Episodes), By Therapy (Pharmacotherapy, Psychotherapy, and Electroconvulsive Therapy (ECT)) and Forecast Period (2026–2035)” at https://www.omrglobal.com/industry-reports/bipolar-disorder-market
Pharma Leaders Accelerate Next-Generation Innovations in the Bipolar Disorder Treatment Market
Key players such as Johnson & Johnson, AbbVie Inc., Bristol Myers Squibb, AstraZeneca plc, and Eli Lilly and Company are advancing bipolar disorder treatment through innovative antipsychotics, mood stabilizers, and long-acting injectable therapies. Their focus on improving treatment adherence, reducing relapse rates, and targeting novel mechanisms such as glutamate modulation is reshaping disease management. Increasing investments in CNS research and strategic partnerships are further accelerating the development of more effective and personalized therapies.
- In March 2026, Otsuka Pharmaceutical Co., Ltd. announced the acquisition of Transcend Therapeutics for up to $1.225 billion to strengthen its neuropsychiatric pipeline. The deal aims to accelerate the development of novel therapies targeting brain neuroplasticity, expanding treatment options across psychiatric disorders. This strategic move reinforces Otsuka’s long-term focus on CNS conditions, including bipolar disorder, and highlights increasing investment in next-generation mental health therapies.
- In January 2026, Johnson & Johnson announced new clinical data from its neuropsychiatry portfolio at the American College of Neuropsychopharmacology (ACNP) Annual Meeting. The data included Phase 3 analyses of CAPLYTA and SPRAVATO targeting major depressive disorder and treatment-resistant depression. The company highlighted its commitment to addressing unmet needs across depression, schizophrenia, and bipolar disorder, reinforcing continued innovation in CNS therapies.
- In November 2024, AbbVie Inc. announced that its Phase II trials for emraclidine in schizophrenia failed to meet primary endpoints, showing no significant improvement over placebo. Despite the setback, the drug demonstrated a favorable safety profile and represents a novel M4 receptor-targeting mechanism. This development highlights the ongoing challenges and innovation focus in CNS drug pipelines, which also impacts advancements in bipolar disorder therapies.
Market Coverage
- The market number available for – 2025–2035
- Base year- 2025
- Forecast period- 2026–2035
- Segment Covered-
- By Drug Class
- By Disorder Type
- By Episode
- By Therapy
- Regions Covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
- Competitive Landscape: Johnson & Johnson, AbbVie Inc., Bristol Myers Squibb, AstraZeneca plc, Eli Lilly and Company, among others.
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- Who is the leader in the market?
- How are players addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Bipolar Disorder Market Report Segment
By Drug Class
- Mood Stabilizers
- Antipsychotics
- Antidepressants
- Combination Therapies
By Disorder Type
- Bipolar I Disorder
- Bipolar II Disorder
- Cyclothymic Disorder
By Episode
- Manic Episodes
- Depressive Episodes
- Mixed Episodes
By Therapy
- Pharmacotherapy
- Psychotherapy
- Electroconvulsive Therapy (ECT)
Global Bipolar Disorder Market Report Segment by Region
North America
- United States
- Canada
Europe
- UK
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
Asia-Pacific
- China
- India
- Japan
- South Korea
- Australia and New Zealand
- ASEAN Economies
- Rest of Asia-Pacific
Rest of the World
- Latin America
- Middle East & Africa
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/bipolar-disorder-market